med-mastodon.com is one of the many independent Mastodon servers you can use to participate in the fediverse.
Medical community on Mastodon

Administered by:

Server stats:

364
active users

#x2F

0 posts0 participants0 posts today

A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg&;kg&;day versus Placebo in the Treatment of Patients with Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse

euclinicaltrials.eu/search-for

euclinicaltrials.euSearch for clinical trials - EMA